ADC drug discovery and hospital channel pharmaceutical manufacturer
Beijing Tide manufactures pharmaceuticals with active R&D in ADC (antibody-drug conjugate) conjugation and target identification. The hiring profile is sales-heavy (41 roles) paired with small research (12) and engineering (2) teams, indicating a commercialization-focused operation scaling hospital distribution channels rather than internal tech infrastructure. Pain points cluster around hospital access restrictions, regulatory compliance, and sales channel management—typical friction points for pharma firms navigating China's tiered healthcare system.
Beijing Tide is a pharmaceutical manufacturing company based in Beijing operating at 1,001–5,000 employees. The company pursues both small-molecule and ADC (antibody-drug conjugate) drug discovery, with active projects in conjugation process development and target identification. Commercial operations focus on hospital market access, including regional business development and community hospital product admission workflows. The organization manages typical pharma operational challenges: regulatory compliance, production quality monitoring, and ROI optimization across sales channels.
Core tools include SAP, Oracle, SAS, Microsoft Office suite, and Chinese ERP platform 用友. Specialized pharma instrumentation: HPLC (chromatography) and CAD for process design. Minimal cloud or modern data infrastructure evident.
Active projects include ADC drug discovery (conjugation process development, target identification), hospital channel expansion (regional business development, community hospital admissions), and M&A financial evaluation. Concurrent focus on lifting hospital access restrictions and product market authorization activities.
Other companies in the same industry, closest in size